

## *Curriculum Vitae*

**Andreani D. Odysseos**

### **Personal Data:**

#### **Date and Place of Birth:**

9<sup>th</sup> of September 1965 - Katokopia, Nicosia-Cyprus

#### **Current address:**

##### **Residence:**

60, Saint Gennadhios Street,

Archangelos, Nicosia 2054

Tel: +357-22-373089

##### **Workplace:**

University of Cyprus

Dept. of Chemistry

75, Kallipoleos Street, Nicosia 1678

Tel: +357-22-892760; +357-99-431729 (personal)

Fax: +357-22-892801

e-mail: [odysseos@ucy.ac.cy](mailto:odysseos@ucy.ac.cy) ; [andreani@epos-iasis.com](mailto:andreani@epos-iasis.com)

### **Education and Professional Experience:**

Graduate of the **Kapodistrian and National University, Medical School** (1988)

Mount Auburn Hospital, **Dept. of Internal Medicine/Harvard Medical School** and

**Dana-Farber Cancer Institute, Department of Tumor Immunology/ Harvard**

**Medical School** (Fellowship, under Professor Christopher Rudd-1988-1995)

**Yale University Medical School as Exchange Fellow** (1992-93)

**Fred-Hutchinson Cancer Research Center /Department of Clinical Research-**

**Special Fellowship Program in Bone Marrow Transplantation** (1995;1997)

**International Agency for Research on Cancer, Regional Programs (with Dr. Annie Sasco, 1998)**

**The Cyprus Institute of Neurology and Genetics, Honorary Research Scientist (1999-2002)**

**University of Cyprus, Department of Chemistry (Special Scientist, Co-ordinating multiple programs on Neoplastic Transformation and Novel Therapeutics/ Translational Cancer Research, Supervising PhD Students, 1999-today)**

**Scientific and Medical Advisor at the Cyprus Paraskevaïdion Bone Marrow Donor Registry (2002-today)**

**High Level Scientific Advisor at DG-Research, European Commission, FP6- 'Life Sciences, Biotechnology and Genetics for Health' (2002-today – <http://www.cordis.lu> ).**

**Co-Founder, Interim CEO and Director of Biomedical Research, EPOS-IASIS, R&D (2006-)**

### **Research Policy and Management Experience:**

**National Contact Point of Cyprus to the Programme Committee, Quality of Life Programme, The EU Fifth Framework Programme for Research and Development (1998-2002)**

**Cancer Research Manager and Human Genome Research Manager of Cyprus at the European Commission (2000-2002)**

**The EU Steering Committee for Integration and Co-ordination of Human Genome Research, DG –Research, European Commission ( 2001-today – <http://forum.europa.eu.int/irc/rtd/cogene/info/data/pub/home.htm>)**

**Co-Founder and Vice-Chairman of the *Section of Medicines Development* of the European Federation of Biotechnology (2004-today, [www.nsmf.org](http://www.nsmf.org), [www.efbweb.org](http://www.efbweb.org) )**

**Vice-Chair, Cluster Management Group, EUREKA Cluster on *New Safe Medicines Faster* ([www.eureka.be](http://www.eureka.be))**

**Member in multiple Academic and Professional Societies**, including the American College of Physicians (1989), the American Medical Association (1989), the Harvard AIDS Institute (1989), Society for Free Radical Research (1998), **Honorary Member**, INTERNATIONAL Academy for Medical Education and Prevention (IAMED) (1999), Council Member of the Federation of European Biochemical Societies (FEBS) (1999-), Council Member, International Union of Biochemistry and Molecular Biology (IUBMB) (2000-), **Editorial Board Member (invited)**, International Journal of Biotechnology and Biochemistry  
**Federation of European Biochemical Societies**, Young Scientists Working Group (2006)

**Organiser of Several Scientific Conferences:**

1. “*The First South East European Conference on Science and Peace: Signal Transduction*” (with UNESCO, Cape Greco, Cyprus, 1999)
2. Seminar: “*Academia meets with Industry – Focus on Drug Discovery*” (under the Research Project *SELAS*, Nicosia, 2000)
3. “*The Inaugural Workshop on Co-ordination of European Human Genome Databases*” (with European Commission, Limassol, Cyprus, 2001)
4. Workshop on “*How to Establish a European Technology Platform for Innovative Medicines*”, ( through an EC-FP6 funded Project, Spain, 2005)
5. European Federation of Biotechnology Bi-annual Congress –EBC 2007: *New Safe Medicines Faster* (Member of the Organising Committee)

## **Entrepreneurial Skills and Experience:**

**1<sup>st</sup> Prize – The Cyprus Entrepreneurship Competition**, “Molecular Imaging in Detection and Treatment of Colorectal Cancer”, 2005

**Co-Founder and Interim CEO** of EPOS-IASIS, R&D, Ltd, a Cyprus-based Biotech Spin-Off introducing Molecular Optical Imaging in Biomarker Identification and Validation for Drug Development and Early Diagnosis

## **Research Experience**

### **Recent Research Programs:**

1. EURODEUCATAM Study: **Multicenter comparative study of second primary cancers after breast cancer – The role of Tamoxifen** (IARC & INSERM)
2. **The role of DFU, a selective COX-2 inhibitor in the primary prevention of familial and sporadic colorectal cancer** (Supported by MSD Inc)
3. **SELAS -Synthesis of novel anticancer agents from selenium and vitamin E compounds** (The Cyprus Research Promotion Foundation)
4. **Analysis of the interaction between Vitamin E compounds and the signal transduction pathway of K-Ras in the carcinogenesis and metastasis of colorectal cancer** (Hellenic-Cypriot Research Cooperation)
5. **COGENE- Co-ordination of Human Genome Across Europe** (European Commission, Fifth Framework Program)
6. **NOSTOS – RPF of Cyprus: Novel poly(oxo)phenolic compounds of selenium with anti-inflammatory and anti-neoplastic properties in IBD**, 2003-2005
7. **PharmTech Platform: Pharmaceutical Development Platforms** with involvement of Biotechnology SMEs–European Commission, 6<sup>th</sup> Framework Program, Strategic Support Action, 2004-2006
8. **InnoMed – Innovative Medicines for Europe**, European Commission 6<sup>th</sup> Framework Program, Integrated Project, 2005-2010 (Co-ordinated by *EFPIA*): Vice-Chair of Education and Training activities (through EFB)
9. **PANACEA - Physical Activity, Nutrition, Alcohol, Cessation of smoking, And Obesity**: European Commission – DG SANCO, 2005-2009

## **Major Areas of Interest:**

Biomarkers in Anti-Cancer and Anti-Inflammatory Drug Development

Early detection and primary prevention of malignancies

Structural Modifications of Natural Compounds for Enhanced Anti-Cancer, Anti-inflammatory and Bone Remodelling Effect

Computational Bioscience for Efficacy and Risk Prediction in Drug Development

### **Selected Publications:**

Rudd CE, Odysseos AD, Burgess KE. An assessment of Protein-Kinase Activity Associated with Human Activation Antigens.. In: *Leucocyte typing IV* 8ed. Knapp W, et al). Oxford University Press, Oxford (1992), 505-507

Odysseos AD, Drotar ME and Rudd CE Regulation of CD4 Associated p56 lck by Antibody Binding to CD4. *J Cell Bioch.* (Abstracts, *19<sup>th</sup> Annual UCLA Symposia.* Suppl.14B,1993

Rudd CE, Barber EK, Burgess KE, Hahn J, Odysseos AD, Syn-Sy, M and Schlossman, SF. Identification of a Physical Association Between the CD4:p56lck and the Ti(TcR)/CD3 Complexes. Rudd CE, Burgess KE, Zalvan C and Odysseos AD (1993) Molecular Aspects of Interaction between p56lck and CD4.. In: *Mechanisms of Lymphocyte Activation and Immune Regulation III* (edits Gupta S., Cooper M., Paul W. and Rothenberg E.) (1994)

Burgess KE, Odysseos AD., Zalvan, C., Schlossman SF and Rudd, CE. Biochemical Identification of a Direct Physical Interaction between the CD4:p56lck and the Ti(TcR)/CD3 Complexes. *Eur J Immunol* July ;(7):1663-1668 *J Cell Bioch.* Suppl 14B., 279,1994

Odysseos AD , Keramidas A. Synthesis of Novel Antineoplastic Compounds from Nutritional Factors., *In Proceedings of EACR-XVI –2000 Meeting*, Halkidiki-Hellas, pg 99, 30 May-4 June, 2000

Odysseos, AD Tocopherols and tocotrienols in the prevention and treatment of colorectal cancer: a model for mechanistic studies in cancer chemoprevention.. *Anticancer Research* 21:3117-3140, 2001

Odysseos AD, Vraka P, Bouralexis S, Frindaly DM, Papas A and Evdokiou A Gamma-tocotrienol triggers caspase-mediated induction of apoptosis in androgen-responsive, but not androgen unresponsive prostate cancer cells *in vitro*. *Free Rad Res*, 36, Suppl.1: 116-118, 2002

Keramidas AD, Drouza C, Rikkou M, Isaac, A and Odysseos AD. Synthesis and study of the *in vitro* cancer cell growth inhibitory properties of a novel selenium- $\alpha$ -tocopherol antioxidant.. *Free Rad Res*, 36, Suppl.1: 118-120, 2002

Vraka PS, Keramidas AD, Drouza C, Rikkou M and Odysseos AD Synthesis and Study of Antioxidant Activity and of the *in vitro* Cancer Cell Growth Inhibitory Properties of Novel Selenium-Vitamin E Antioxidants. Abstracts, *Frontiers in*

Chemical Biology: The Chemical Biology of Cancer, pg 19, London UK 8-10 Sept 2004

Keramidas AD, Drouza C, Rikkou MP, Isaak A, Braka P, Odysseos AD. Enhancement of selenium bioavailability utilizing novel selenium tocopherol compounds. *European Journal of Pharmaceutical Sciences* 23:S71-S72 Suppl. 1 Oct 2004

A. D. Odysseos, P. S. Vraka, V. Liapis, S. Hay and A. Evdokiou. Synergistic induction of prostate cancer cell death by  $\gamma$ -tocotrienol and lovastatin is mediated by direct geranylgeranyl pyrophosphate inhibition through a caspase-independent pathway. *The FEBS Journal*. Volume 272 Suppl.1:40-41, July 2005

P.S. Vraka, A.D. Keramidas, C. Drouza, M. Rikkou and A.D. Odysseos. Investigation of cancer cell growth inhibitory effects of new selenium phenolic succinate antioxidants. *The FEBS Journal*. Volume 272 Suppl.1: 430-431. July 2005

Vraka PS, Drouza C, Rikkou MP, Odysseos AD and Keramidas AD. Synthesis and study of the cancer cell growth inhibitory properties of  $\alpha$ -,  $\gamma$ -tocopheryl and  $\gamma$ -tocotrienyl 2-phenylselenyl succinates. *Bioorganic and Medicinal Chemistry* 14 (2006) 2684-2696

Vraka PS, Rikkou MP, Drouza D, Odysseos AD, Keramidas AD. Synthesis of novel vitamin E-selenium antioxidants and study of their antiproliferative and apoptotic properties. *Proc Amer Assoc Cancer Res* 2006;47:1130

**Patents:**

**US patent 6,716,873 entitled *Tocopherol ester compounds***